Advances in erythropoietic growth factor therapy for myelodysplastic syndromes

Expert Opinion on Biological Therapy

Volumn 6, Issue 11, 2006, Pages 1099-1104

  Mundle, Suneel D ^a,b  

^a Ortho Biotech Products LP   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Erythroid response; Erythropoietin; Myelodysplastic syndromes

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EVALUATION; HUMAN; META ANALYSIS; MYELODYSPLASTIC SYNDROME; PATIENT SELECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 33750812514     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.11.1099     Document Type: Review

References (28)

1. MUNDLE S: Intramedullary apoptosis: a biologic hallmark of myelodysplastic syndromes. In: The Molecular and Cellular Pathology of Cancer Progression and Prognosis. Sherbet G (Ed.), Research Signpost Press, Kerala, India (2006):431-444. Overview of apoptosis, a major pathobiological feature of MDS.
2. STEENSMA DP, BENNETT JM: The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin. Proc. (2006) 81:104-130.
3. KAMINSKAS E, FARRELL AT, WANG YC, SRIDHARA R, RAZDUR R: FDA drug approval summary: azacicidine (5-azacytidine, Vidaza™) for injectable suspension. The Oncologist (2005) 10:176-182.
4. KANTARJIAN H, ISSA JP, ROSENFELD CS et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer (2006) 106:1794-1803.
5. CRANE E, LIST AF: Lenalidomide: an immunomodulatory drug. Future Oncol (2005) 1:575-583.
6. HELLSTRÖM-LINDBERG E: Efficacy of erythropoietin in the myelodysplastic syndromes: meta-analysis of 205 patients from 17 studies. Br. J. Haematol. (1995) 89:67-71. First meta-analysis of EPO therapy in MDS.
7. CLAVIO M, BALLEARI B, GARRONE A et al.: Haematopoietic growth factors in myelodysplastic syndromes: toward patient-oriented therapy? J. Exp. Clin. Cancer Res. (2005) 24:5-16. Overview of different clinical trials using hematopoietic growth factors in MDS.
8. CATENACCI DV, SCHILLER GJ: Myelodysplastic syndromes: a comprehensive review. Blood Rev. (2005) 19:301-319.
9. ALOE SPIRITI MA, LATAGLIATA R, NISCOLA P et al.: Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplatic syndrome. Ann. Hematol. (2005) 84:167-176.
10. CLAVIO M, NOBILI F, BALLEARI E et al.: Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. Eur. J. Haematol. (2004) 72:113-120.
11. MANNONE L, GARDIN C, QUARRE MC et al.: High dose darbepoetin alpha in the treatment of anemia of lower risk myelodysplastic syndrome: results of a Phase II study. The Groupe Francais des Myelodysplasies (GFM). Br J. Haematol. (2006) 133:513-519.
12. TERPOS E, MOUGIOU A, KOURAKLIS A et al.: Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a Phase II trial in 281 patients. The Greek MDS Study Group. Br. J. Haematol. (2002) 118:174-180.
13. TEHRANCHI R, FADEEL B, FORSBLOM AM et al.: Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood (2003) 101:1080-1086.
14. KASPER C, ZAHNER J, SAYER HG: Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J. Cancer Res. Clin. Oncol. (2002) 128:497-502.
15. JÄDERSTEN M, MONTGOMERY SM, DYBEDAL I, PORWIT-MACDONALD A, HELLSTRÖM-LINDBERG E: Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood (2005) 106:803-811. Addresses safety and efficacy of EPO therapy in MDS with a long-term follow-up.
16. BALLEARI E, ROSSI E, CLAVIO M et al.: Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-center study. Ann. Hematol. (2006) 85:174-180.
17. HELLSTRÖM-LINDBERG E: Update on supportive care and new therapies:immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology (Am. Soc. Hematol. Educ. Prog.) (2005):161-166.
18. WALLVIK J, STENKE L, BERNELL P, NORDAHL G, HIPPE E, HAST R: Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur. J. Haematol. (2002) 68:180-186.
19. CHESON BD, BENNETT JM, KANTARJIAN H et al.: Report of an international working group to standardize response criteria for myelodysplastic syndromes. World Health Organization (WHO) international working group. Blood (2000) 96:3671-3674. First standardised criteria for response evaluation in MDS.
20. CHESON BD, GREENBERG PL, BENNETT JM et al.: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 108(2):419-425. Revised IWG criteria for response evaluation in MDS.
21. MOYO V, LEFEBVRE P, DUH MS et al.: Erythroid response (ER) rates in myelodysplastic syndromes (MDS) patients treated with epoetin alfa (EPO): a meta-analysis using the international working group criteria (IWGc) for MDS response. J. Clin. Oncol. (2006) 24(18S):354s (Abstract 6572).
22. HELLSTRÖM-LINDBERG E, NEGRIN R, STEIN R et al.: Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br. J. Haematol. (1997) 99:344-351. Describes the patient selection model to determine suitability for treatment with EPO ± GCSF.
23. GREENBERG P, COX C, LEBEAU MM et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89:2079-2088. IPSS risk assessment in MDS.
24. STASI R, BRUNETTI M, TERZOLI E, ABRUZZESE E, AMADORI S: Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. Ann. Oncol. (2004) 15:1684-1690.
25. PATTON JF, SULLIVAN T, MUN Y, REEVES T, ROSSI G, WALLACE JF: A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndromes. J. Support. Oncol. (2005) 3:419-426.
26. MUSTO P, LANZA F, BALLEARI E et al.: Darbepoetin alpha for the treatment of anemia in low-intermediate risk myelodysplastic syndromes. Br. J. Haematol. (2004) 128:204-209.
27. STASI R, ABRUZZESE E, LANZETTA G, TERZOLI E, AMADORI S: Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann. Oncol. (2005) 16:1921-1927.
28. www.nccn.org NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. Version 4, 2006. see p7-9.